January 2026Biotech 2026: What Comes After a Breakthrough Year
2025 was not just another productive year for biotech. Multiple technologies reached new levels of practical impact. Here is what comes next.
Read breakdown →Monthly Biotech & AI Research Breakdowns
One breakthrough. Every month. Decoded.
Monthly, hype-free breakdowns of biotech and AI research — methods, limitations, and what findings actually mean — from a high school researcher in Bentonville, Arkansas.
About ReadingFrame
Biotech and AI research, explained without the hype
ReadingFrame is a monthly research blog that breaks down one biotech or AI paper at a time. Every issue covers a single development — a CRISPR delivery method, a gene therapy approval, a brain–computer interface trial, an AI drug-discovery model — and explains the methods, the limitations, and what the finding actually means. No press releases, no breathless headlines, no affiliate links.
It's written by Heram Nagabhairu, a high school researcher in Bentonville, Arkansas who works in machine learning and bioinformatics. One post a month, aimed at students, scientists, and anyone who wants the substance of new research instead of the spin.
Recent breakdowns
View all posts →Explore the archive
Showing all 8 posts.
January 2026
Featured topics
What gets covered here
Breakdowns cluster around a few recurring themes. Pick one to read every post on that subject.
Biotech
Gene editing, therapeutics, and the systems that move discoveries from lab to clinic.
Read Biotech posts →CRISPR
Delivery, safety, and clinical translation of programmable genome editing.
Read CRISPR posts →AI & ML
Machine learning in drug discovery, biomedicine, and biological data analysis.
Read AI & ML posts →Neuroscience
Brain-computer interfaces and neural technology with real trial data.
Read Neuroscience posts →De-extinction
Engineered organisms, conservation claims, and what the science actually shows.
Read De-extinction posts →The method
How I break down each paper
Most science coverage stops at the headline. The goal here is to go one layer deeper without drowning you in jargon. Every breakdown follows the same three questions:
What was actually done
The real method — the model, the edit, the trial — stated plainly, separated from the marketing around it.
Where the limits are
Sample sizes, what hasn't been shown yet, and the gap between a lab result and a real-world treatment.
Why it matters
What changes if the finding holds up — and an honest read on whether it likely will.
Monthly newsletter
One breakthrough per month — decoded in your inbox. No hype, no spam.
Author spotlight
Heram Nagabhairu
Student researcher · Bentonville, AR
I'm a high school researcher interested in ML, bioinformatics, and computational biology. ReadingFrame is where I write about one paper or development a month — without the press release layer.
- Cancer biology & AI
- Graph neural networks
- Gene expression analysis
- Drug resistance prediction
- Bioinformatics pipelines